December 25th 2023, 10:00pm
Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.
December 20th 2023, 2:00pm
Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.
December 19th 2023, 2:00pm
A treatment combination of Sarclisa, Kyprolis, Revlimid and dexamethasone demonstrated a complete response in patients who were newly diagnosed with multiple myeloma.
December 17th 2023, 2:00pm
A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.
December 14th 2023, 4:00pm
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
December 13th 2023, 10:00pm
Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of Yescarta for patients with high-risk large B-cell lymphoma.
December 13th 2023, 4:00pm
Dr. Lucia Masarova sat down with CURE® and discussed the advancements she hopes to see in 2024 for the treatment of patients with myeloproliferative neoplasms.
December 12th 2023, 10:00pm
Children and adults with relapsed/refractory KMT2A rearranged acute leukemia may obtain promising response rates with revumenib, a novel targeted therapy.
December 12th 2023, 8:00pm
Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity.
December 12th 2023, 4:00pm
A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.
FDA Approves Imdelltra For Advanced SCLC
Erleada, ADT ‘One-Two Punch’ in Prostate Cancer Treatment
My ‘Bag of Tricks’ Helps Overcome Fear During Stage 4 Ovarian Cancer
Adding Tecentriq to Chemo Did Not Boost TNBC Survival